Cite
Bever KM, Borazanci EH, Thompson EA, et al. An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncotarget. 2020;11(21):1929-1941doi: 10.18632/oncotarget.27586.
Bever, K. M., Borazanci, E. H., Thompson, E. A., Durham, J. N., Pinero, K., Jameson, G. S., Vrana, A., Liu, M., Wilt, C., Wu, A. A., Fu, W., Wang, H., Yin, Y., Leal, J. P., Jesus-Acosta, A., Zheng, L., Laheru, D. A., Von Hoff, D. D., Jaffee, E. M., Powell, J. D., & Le, D. T. (2020). An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncotarget, 11(21), 1929-1941. https://doi.org/10.18632/oncotarget.27586
Bever, Katherine M, et al. "An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma." Oncotarget vol. 11,21 (2020): 1929-1941. doi: https://doi.org/10.18632/oncotarget.27586
Bever KM, Borazanci EH, Thompson EA, Durham JN, Pinero K, Jameson GS, Vrana A, Liu M, Wilt C, Wu AA, Fu W, Wang H, Yin Y, Leal JP, Jesus-Acosta A, Zheng L, Laheru DA, Von Hoff DD, Jaffee EM, Powell JD, Le DT. An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncotarget. 2020 May 26;11(21):1929-1941. doi: 10.18632/oncotarget.27586. eCollection 2020 May 26. PMID: 32523648; PMCID: PMC7260120.
Copy
Download .nbib